Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Linder

Showing results (1-10 of 108) with videos related to

Pageof 11
Sort By:
Critical Care Medicine|January 20, 2015
The authors replyAdam Linder, James A Russell
Intensive Care Medicine|July 4, 2014
An exciting candidate therapy for sepsis: ulinastatin, a urinary protease inhibitorAdam Linder, James A Russell
Journal of Innate Immunity|May 28, 2010
Roles of heparin-binding protein in bacterial infectionsAdam Linder, Oliver Soehnlein, Per Akesson
Expert Review of Anti-Infective Therapy|November 23, 2025
Early recognition of sepsis should be an integral part of antimicrobial stewardship programsKristoffer Strålin, Ulrika Knutsson, Adam Linder
Pediatric Nephrology (Berlin, Germany)|March 14, 2012
Elevated urine levels of heparin-binding protein in children with urinary tract infectionCharlott Kjölvmark, Per Akesson, Adam Linder
BMC Infectious Diseases|June 3, 2014
Recurrent erysipelas--risk factors and clinical presentationMalin Inghammar, Magnus Rasmussen, Adam Linder
Intensive Care Medicine Experimental|January 9, 2019
Elevated plasma glypicans are associated with organ failure in patients with infectionJane Fisher, Adam Linder, Peter Bentzer
Open Forum Infectious Diseases|December 4, 2015
Public Awareness of Sepsis Is Low in SwedenLisa Mellhammar, Bertil Christensson, Adam Linder
BMJ Open|February 22, 2023
Use of healthcare before and after sepsis in Sweden: a case-control studyJacob Dahlberg, Adam Linder, Lisa Mellhammar
Critical Care (London, England)|August 25, 2010
Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromesCarl Ekman, Adam Linder, Per Akesson, et al.
Pageof 11

Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
Critical Care Medicine|January 20, 2015
The authors replyAdam Linder, James A Russell
Intensive Care Medicine|July 4, 2014
An exciting candidate therapy for sepsis: ulinastatin, a urinary protease inhibitorAdam Linder, James A Russell
Journal of Innate Immunity|May 28, 2010
Roles of heparin-binding protein in bacterial infectionsAdam Linder, Oliver Soehnlein, Per Akesson
Expert Review of Anti-Infective Therapy|November 23, 2025
Early recognition of sepsis should be an integral part of antimicrobial stewardship programsKristoffer Strålin, Ulrika Knutsson, Adam Linder
Pediatric Nephrology (Berlin, Germany)|March 14, 2012
Elevated urine levels of heparin-binding protein in children with urinary tract infectionCharlott Kjölvmark, Per Akesson, Adam Linder
BMC Infectious Diseases|June 3, 2014
Recurrent erysipelas--risk factors and clinical presentationMalin Inghammar, Magnus Rasmussen, Adam Linder
Intensive Care Medicine Experimental|January 9, 2019
Elevated plasma glypicans are associated with organ failure in patients with infectionJane Fisher, Adam Linder, Peter Bentzer
Open Forum Infectious Diseases|December 4, 2015
Public Awareness of Sepsis Is Low in SwedenLisa Mellhammar, Bertil Christensson, Adam Linder
BMJ Open|February 22, 2023
Use of healthcare before and after sepsis in Sweden: a case-control studyJacob Dahlberg, Adam Linder, Lisa Mellhammar
Critical Care (London, England)|August 25, 2010
Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromesCarl Ekman, Adam Linder, Per Akesson, et al.
Pageof 11